Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Kyntra Bio, Inc. Secures Amended Financing Agreement Reducing Payment Obligations
Sep 01, 2026•about 13 hours ago
BiotechnologyHealth Care
Description
On August 31, 2026, Kyntra Bio, Inc. entered into an amended agreement with NQ Project Phoebus, significantly reducing its total payment obligations. The maximum aggregate payments were decreased from $125 million to $65 million, providing the company with a $60 million reduction in its obligations. An upfront payment of $42.6 million was made at the signing of the new agreement.
Company Information
Company
Kyntra Bio
About
Kyntra Bio, Inc. is a biotechnology company based in San Francisco, California. The company focuses on developing innovative therapies and solutions in the biotech sector. Kyntra Bio seeks to advance healthcare through its research and development initiatives. The team is committed to creating impactful products that meet patient needs.
